These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 9854493)
1. Limitations in the use of glutathione S-transferase P1 in urine as a marker for bladder cancer. Lafuente A; Rodriguez A; Gibanel R; Lafuente MJ; Alonso M; Molina R; Ballesta A; Carretero P Anticancer Res; 1998; 18(5B):3771-2. PubMed ID: 9854493 [TBL] [Abstract][Full Text] [Related]
2. Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer. Berendsen CL; Mulder TP; Peters WH J Urol; 2000 Dec; 164(6):2126-8. PubMed ID: 11061940 [TBL] [Abstract][Full Text] [Related]
3. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433 [TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
5. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Jamshidian H; Kor K; Djalali M Urol J; 2008; 5(4):243-7. PubMed ID: 19101898 [TBL] [Abstract][Full Text] [Related]
6. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921 [TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma. Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536 [TBL] [Abstract][Full Text] [Related]
9. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma. Bian W; Xu Z Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565 [TBL] [Abstract][Full Text] [Related]
10. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254 [TBL] [Abstract][Full Text] [Related]
11. Cellular fibronectin in patients with transitional cell carcinoma of the bladder. Hegele A; Heidenreich A; Varga Z; von Knobloch R; Olbert P; Kropf J; Hofmann R Urol Res; 2003 Feb; 30(6):363-6. PubMed ID: 12599015 [TBL] [Abstract][Full Text] [Related]
12. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University. Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356 [TBL] [Abstract][Full Text] [Related]
13. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562 [TBL] [Abstract][Full Text] [Related]
14. Glutathione S-transferase T1-1 activity upregulated in transitional cell carcinoma of urinary bladder. Simic T; Mimic-Oka J; Savic-Radojevic A; Opacic M; Pljesa M; Dragicevic D; Djokic M; Radosavljevic R Urology; 2005 May; 65(5):1035-40. PubMed ID: 15882759 [TBL] [Abstract][Full Text] [Related]
15. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813 [TBL] [Abstract][Full Text] [Related]
16. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628 [TBL] [Abstract][Full Text] [Related]
17. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416 [TBL] [Abstract][Full Text] [Related]
19. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder. Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]